Vallon Pharmaceuticals

General Information

We are a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing prescription drugs for central nervous system (CNS) disorders and our current focus is the development of drugs with lower potential for abuse than currently available drugs. Our clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, or ADHD, and narcolepsy.

(Note: Vallon Pharmaceuticals priced its IPO on Feb. 9, 2021, at 2.25 million shares – selling 580,000 more shares than the 1.67 million in the prospectus – at $8 each, the low end of its $8-to-$10 price range, to raise $18 million.)

Employees: 1
Founded: 2018
Contact Information
Address Two Logan Square, 100 N. 18th Street, Suite 300, Philadelphia, PA 19103, US
Phone Number (267) 207-3606
Web Address
View Prospectus: Vallon Pharmaceuticals
Financial Information
Market Cap $55.0mil
Revenues $0.1 mil (last 12 months)
Net Income $-2.3 mil (last 12 months)
IPO Profile
Symbol VLON
Exchange NASDAQ
Shares (millions): 2.3
Price range $8.00 - $8.00
Est. $ Volume $18.0 mil
Manager / Joint Managers ThinkEquity
CO-Managers -
Expected To Trade: 2/10/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change